Kosh Agarwal - Dissemin

Papers authored by Kosh Agarwal

This paper was not found in any repository, but could be made available legally by the author.

2019 Daniel Bradshaw, Jean L. Mbisa, Anna Maria Geretti, Brendan J. Healy, Graham S. Cooke, Graham R. Foster

, Emma C. Thomson, John McLauchlan, Kosh Agarwal

, Caroline Sabin, David Mutimer, Peter Moss, William L. Irving, Ellie Barnes

Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group

Upload

Sergio M. Borgia

, Janet Dearden, Eric M. Yoshida, Stephen D. Shafran, Ashley Brown, Ziv Ben-Ari, Matthew E. Cramp, Curtis Cooper, Matthew Foxton, Conrado Fernandez Rodriguez, Rafael Esteban, Robert Hyland, Sophia Lu, Brian J. Kirby, Amy Meng and 14 other authors

Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis

Upload

Cheng Fang

, Sanjiv Virdee, Joseph Jacob, Olivia Rufai, Kosh Agarwal

, Alberto Quaglia, Daniel J. Quinlan, Paul S. Sidhu

Strain elastography for noninvasive assessment of liver fibrosis: A prospective study with histological comparison

Upload

This paper is made freely available by the publisher.

Ondrej Podlaha, Edward Gane, Maurizia Brunetto, Scott Fung, Wan-Long Chuang, Calvin Q. Pan, Zhaoshi Jiang, Yang Liu, Neeru Bhardwaj, Prasenjit Mukherjee, John Flaherty, Anuj Gaggar, Mani Subramanian, Namiki Izumi, Shalimar

and 5 other authors

Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients

Download from www.nature.com

Zobair M. Younossi

, Maria Stepanova, Issah Younossi, George Papatheodoridis

, Harry L. A. Janssen, Kosh Agarwal

, Mindie H. Nguyen

, Ed Gane, Naoky Tsai, Fatema Nader

Patient‐reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Rafael Esteban, Kosh Agarwal

, Jose Luis Calleja, Jean-Francois Dufour, Steven Flamm, Stuart Gordon, Luisa Stamm, Liyun Ni, Diana Brainard, Christina Sze Man Yip, Kris Kowdley, Curtis Cooper, Juan Antonio Pineda, Lluis Castells, Maria Buti and 1 other authors

IDDF2019-ABS-0134 Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies

Upload

Henry Lik Yuen Chan, Pietro Lampertico, Maria Buti, Scott Fung, Sang Hoon Ahn, Wan-Long Chuang, Won Young Tak, Alnoor Ramji, Chi-Yi Chen, Edward Tam, Ho Bae, Xiaoli Ma, John Flaherty, Anuj Gaggar, Audrey Lau and 8 other authors

IDDF2019-ABS-0169 A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results

Upload

Pietro Lampertico, Maria Buti, Scott Fung, Sang Hoon Ahn, Wan-Long Chuang, Alnoor Ramji, Won Young Tak, Chiyi Chen, Edward Tam, Ho Bae, Xiaoli Ma, John F. Flaherty, Anuj Gaggar, Audrey Lau, Becket Feierbach and 8 other authors

FRI-183-A phase 3 study comparing switching from tenofovir disoproxil fumarate to tenofovir alafenamide with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results

Upload

Xiaoli Ma, Jacob Lalezari, Tuan Nguyen, Ho Bae, Eugene R. Schiff, Scott Fung, Man-Fung Yuen, Tarek Hassanein, Hie-Won Hann, Magdy Elkhashab, Douglas Dieterich, Mark Sulkowski, Paul Kwo, Ronald Nahass, Kosh Agarwal

and 17 other authors

LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients

Upload

Ivana Carey, Jeffrey Gersch, Matthew Bruce, Bo Wang, Mary Kuhns, Gavin Cloherty, Geoffrey Dusheiko, Kosh Agarwal

FRI-159-Can HBcrAg and pre-genomic HBV RNA predict the risk of ALT flares after nucleoside analogue therapy withdrawal: delineating the clinical utility of new biomarkers?

Upload

Bo Wang, Jeffrey Gersch, Mary Horner, Mary Kuhns, Gavin Cloherty, Geoffrey Dusheiko, Kosh Agarwal

, Ivana Carey

FRI-213-HBV RNA at 6 months predicts HBeAg loss in nucleos (t)ide analogue treated HBeAg positive patients: Demonstration of clinical utility?

Upload

Jeremy Nayagam, Oliver Tavabie

, Benjamin Norton, Deepak Joshi, Abid Suddle, John O’grady, Wayel Jassem, Krishna Menon, William Bernal, Nigel Heaton, Kosh Agarwal

, Michael Heneghan, Varuna Aluvihare

FRI-387-Risk factors associated with early post-operative acute kidney injury requiring renal replacement therapy following liver transplantation

Upload

Oliver Tavabie

, Robert Adamson, Deepak Joshi, Abid Suddle, William Bernal, Wayel Jassem, Michael Heneghan, Varuna Aluvihare, Kosh Agarwal

FRI-397-Sepsis is a major risk factor for delirium post liver transplantation

Upload

Kate Childs, Chris Davis, Mary D. Cannon, Matthew Bruce, Geoff Dusheiko, Emma Thomson, Kosh Agarwal

PS-181-Unacceptably low SVR rates in African patients with unusual HCV sub-genotypes : Implications for global elimination

Upload

Gregory Dore, Jordan Feld, Alexander Thompson, Marianne Martinello, Andrew Muir, Kosh Agarwal

, Beat Müllhaupt, Heiner Wedemeyer, Karine Lacombe, Gail Matthews, Michael Schultz, Gerard Estivill Mercade, Danny Kho, Ecaterina Filep, Kathy Petoumenos and 4 other authors

PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study

Upload

Patrick R. Shea, Sarah Kleinstein, Nicholas Stong, Edward Gane, Kosh Agarwal

, Zhaoshi Jiang, John F. Flaherty, Vithika Suri, Anuj Gaggar, Mani Subramanian, Maria Buti, Wan-Long Chuang, Scott Fung, David Goldstein

THU-233-Whole exome sequencing analysis of the role of rare human variation in chronic hepatitis B infection

Upload

Sarah Brown, Anne Langan, Pauline Kane, Nigel Heaton, Kosh Agarwal

, William Bernal

SAT-018-Relation of CT determined sarcopenia and anthropometry to serum C-reactive protein levels in patients with chronic liver disease

Upload

Ivana Carey, Jeffrey Gersch, Matthew Bruce, Christiana Moigboi, Bo Wang, Mary Kuhns, Gavin Cloherty, Geoffrey Dusheiko, Kosh Agarwal

PS-055-The markers of HBV transcriptional activity-HBcrAg and pre-genomic HBV DNA during antiviral therapy with nucleos (t)ide analogue help to predict optimal timing of therapy withdrawal

Upload

Ivana Carey, Jeffrey Gersch, Christiana Moigboi, Matthew Bruce, Mary Kuhns, Gavin Cloherty, Geoffrey Dusheiko, Kosh Agarwal

THU-206-HBV DNA relapse after stopping nucleoside analogue therapy in patients with HBsAg loss: Detectable pre-genomic HBV RNA is a better predictor of relapse than ultra-sensitive HBsAg-‘implications for HBV cure’

Upload

Michael Trauner, Aliya Gulamhusein, Bilal Hameed, Stephen Caldwell, Mitchell L. Shiffman, Charles Landis, Bertus Eksteen, Kosh Agarwal

, Andrew Muir, Simon Rushbrook, Xiaomin Lu, Jun Xu, Jen‐Chieh Chuang, Andrew N. Billin, Georgia Li and 5 other authors

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

Upload

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

Papers authored by Kosh Agarwal